BioThrust

What BioThrust does

BioThrust GmbH is an Aachen, Germany-based biotech company founded in 2022 that develops the ComfyCell bioreactor platform, built around its proprietary Membrane Stirrer technology—a patent-protected system integrating gas-permeable hollow-fiber membranes with the mixing impeller to deliver bubble-free aeration. The Membrane Stirrer enables 10-fold higher gas transfer rates (kLa), 99% reduced shear forces compared with conventional stirred-tank bioreactors, and complete elimination of foam, thereby removing the trade-off between oxygen supply and cell damage that constrains conventional bioreactors. The product portfolio spans reusable glass vessels (250 mL–10 L), single-use closed-system vessels (300 mL–12 L), a touchscreen controller with four mass flow controllers, and an incubator-compatible 300 mL unit (ComfyCell Incu), with linear scalability from 150 mL to 200 L working volume.

The platform addresses commercial-scale manufacturing bottlenecks in cell therapy and biologics production, with documented outcomes including a world-record 44 million hiPSCs/mL, 258 million CHO cells/mL with 60 g/L protein titer (4x STR control), 600-fold expansion of primary NK cells at G-Rex quality, and >327-fold iNK expansion (>1000-fold from thaw). BioThrust serves cell therapy developers, biopharmaceutical manufacturers (CHO/protein), CDMOs, and academic/research institutions, with named collaborations including Catalent, Fraunhofer IPT/IZI, University of Cologne, University Hospital Essen, and TU Vienna.

The company operates a direct enterprise sales model—combining inbound contact forms, video technical-fit interviews, on-site visits to the Aachen facility, conference presence, and a content-driven funnel (application studies, peer-reviewed publications, blog)—supplemented by equipment financing models and process development services. Revenue is generated through bioreactor hardware sales and rentals, single-use consumables, controllers, and professional services, with multi-year contract structures. BioThrust has secured seed funding from Freigeist Capital (January 2024), selection in the EIC Accelerator (October 2024 and February 2025), additional investment from Alago Familien Stiftung, NRW.BANK, and RWTH Aachen University, and Falling Walls 2025 Venture Finalist recognition.

Name

BioThrust

Legal name

BioThrust GmbH

Website

https://biothrust.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

BioThrust GmbH develops the ComfyCell bioreactor platform with proprietary Membrane Stirrer technology for bubble-free aeration, serving cell therapy developers, biopharmaceutical manufacturers, CDMOs, and academic researchers in scalable, low-shear cell cultivation.

Ownership category

akta.pro rank

Product category

Bioprocessing Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Laboratory Apparatus & Furniture (3821)

akta.pro primary industry

Upstream Bioprocessing Systems & Equipment (cell culture/fermentation, bioreactors, feeds/media) (HLAAAJAA)

akta.pro secondary industry

Process Analytical Technology (PAT) & In-Line/At-Line Analytics (spectroscopy, sensors, monitoring) (HLAAAJAD)

Keywords

• Bioreactor systems
• Cell therapy manufacturing
• Membrane aeration technology
• Single-use bioreactors
• Bioprocess equipment

Headquarters

HQ city

Aachen

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Bioreactor Hardware Sales: BioThrust sells and rents bioreactor systems including reusable glass vessels (250mL-10L) and single-use vessels (300mL-200L), along with compatible controller units. The company offers 'short delivery times, attractive financing models' suggesting flexible purchase and rental options.
2. Process Development Services: The company provides process experts to support customers in implementing ComfyCell bioreactors, suggesting technical support and consulting as revenue streams.
3. Financing Models: BioThrust offers 'attractive financing models' for their ComfyCell platform, suggesting equipment financing or leasing arrangements.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

BioThrust designs, manufactures, and sells the ComfyCell bioreactor platform — a scalable stirred-tank bioreactor system featuring the proprietary Membrane Stirrer for bubble-free aeration. The platform includes reusable glass vessels, single-use vessels, a touchscreen controller, and the incubator-compatible Incu unit, and is paired with process development support for cell therapy and biopharmaceutical customers.

Product overview

BioThrust offers the ComfyCell platform, the world's first and only scalable bioreactor with high gas transfer, low shear force, and no foaming. The platform is a unified system consisting of proprietary bionic bioreactor vessels (available as reusable glass or single-use configurations) paired with a compatible controller unit. The core innovation is the BioThrust Membrane Stirrer technology, which integrates gas-permeable hollow-fiber membranes with the mixing system to enable bubble-free aeration. Product portfolio includes: reusable glass vessels (250 mL to 10 L), single-use closed-system vessels (300 mL to 12 L), a bioreactor controller with touchscreen interface and four mass flow controllers, and the incubator-compatible BioThrust Incu (300 mL). The platform scales from 150 mL to 200 L working volume while maintaining consistent process conditions.

Differentiator

Problem solved

Functional benefit

Brands

• ComfyCell: BioThrust's bionic bioreactor product line including reusable and single-use vessels for cell therapy manufacturing
• ComfyCell Incu
• ComfyCell Benchtop
• Membrane Stirrer
• MemStir

Products and services

• ComfyCell Bioreactor Platform Flagship bionic bioreactor platform featuring the proprietary Membrane Stirrer for bubble-free aeration, high gas transfer, and low shear. Available in reusable glass (250 mL to 10 L) and single-use (300 mL to 12 L) configurations, paired with a controller unit. Scales linearly from 150 mL to 200 L working volume. Targets cell therapy developers, CDMOs, and academic researchers in biopharmaceutical manufacturing.
• BioThrust Controller Bioprocess controller with touchscreen interface and configurable process profiles. Equipped with four mass flow controllers and four fast-load pumps for precise bioprocess management and a small footprint. Pairs with ComfyCell vessels for cell therapy and biologics manufacturing.
• BioThrust Incu (Incubator Bioreactor) Single-use 300 mL vessel bioreactor designed to fit inside a standard incubator. Includes an integrated active pump for Membrane Stirrer operation and a user-friendly interface to control agitation and aeration. Intended for early-stage 3D cell therapy research and small-batch production.
• BioThrust Reusable Glass Vessel Autoclavable reusable glass vessels available from 250 mL to 10 L, with a replaceable BioThrust Membrane Stirrer for repeated use in bioprocess development and manufacturing applications. Designed for cost-efficient repeated-use campaigns.
• BioThrust Single-Use Vessel (SUB) Closed-system single-use bioreactor vessels available from 300 mL to 12 L, equipped with in-process sensors for temperature, dissolved oxygen, and pH, and an integrated BioThrust Membrane Stirrer for bubble-free aeration. Designed for GMP-relevant cell therapy and biopharmaceutical manufacturing.
• Process Development and Application Support Services Process development services delivered by BioThrust bioprocess experts to support customer implementation of ComfyCell bioreactors, including application studies, process transfer, and on-site consultation. Targeted at cell therapy developers, CDMOs, and academic groups adopting the platform.

Quantifiable outcome

• 44 million hiPSCs per mL - World record cell density achieved in 300mL bioreactor using in-situ perfusion
• +7 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Ten partnerships are on record, tiered core, secondary and minor.

• Fraunhofer IPTcoreStrategic or Co-development PartnerPartners at Fraunhofer IPT achieved over 600k iMSCs per mL in BioThrust's 2L ComfyCell bioreactor under project RauPE, funded by EU and Ministry of Industry of NRW. Process was integrated into Autostem automated platform.
• Fraunhofer IZIcoreStrategic or Co-development PartnerWithin the SaxoCell cluster, Fraunhofer IZI used ComfyCell 300mL to achieve 600-fold expansion of primary NKs (up to 3.6E6 cells/mL) while maintaining NK receptor, purity, and advanced cytotoxicity.
• University of ColognecoreStrategic or Co-development PartnerPartners at University of Cologne successfully expanded preformed embryoid bodies in 2L Membrane Stirrer bioreactor, achieving over 200 million cardiomyocytes after 7 days with excellent differentiation. Process being transferred to GMP.
• University Hospital EssencoreStrategic or Co-development PartnerProf. Dr. Bernd Giebel focuses on manufacturing extracellular vesicle products from conditioned media of MSCs. The team considers BioThrust's bionic bioreactor concept as the most promising 3D bioreactor process for scaled and robust upstream processing.
• TU ViennasecondaryStrategic or Co-development PartnerPartners at TU Vienna benchmarked 2L ComfyCell against classic STR and found that Membrane Stirrer's homogeneous shear distribution improves NK-92 cell cytotoxicity while avoiding foaming completely.
• CatalentcoreStrategic or Co-development PartneriNK cells were expanded by Catalent in BioThrust's 300mL SUB and 2L reusable system, proving simplicity of upscaling with ComfyCell. Achieved >327-fold expansion (>1000-fold from thaw) with >3E9 cells in a batch.
• InVivo BiosystemssecondaryStrategic or Co-development PartnerInVivo Biosystems tested ComfyCell Incu for C. elegans liquid cultures and found significant improvement over previous methods in age synchronization, development, animal health, and culture contamination for drug discovery applications.
• RWTH Aachen UniversitycoreStrategic or Co-development PartnerBioThrust operates from RWTH campus with science lab and office facilities. Company originated from technical university research and maintains close ties for talent and research collaboration.
• Bio.R.N.minorStrategic or Co-development PartnerBioRegioN competition/network in Rhine-Neckar region supporting biotech companies; listed as partner in BioThrust's ecosystem.
• SaxoCellcoreStrategic or Co-development PartnerSaxoCell cluster focusing on cell therapy development; Fraunhofer IZI's NK cell work within this cluster used BioThrust's ComfyCell technology.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Sartorius: Global bioprocess leader offering ambr, Biostat, and single-use bioreactor families for cell therapy and biopharma. Competes with BioThrust at the upstream bioprocessing equipment layer with much larger commercial reach.
• Thermo Fisher Scientific: Through its bioproduction and cell therapy businesses (including former Finesse assets), offers bioreactors, controllers, and single-use systems. Broad incumbent with overlapping customer base and much greater commercial scale.
• Corning Life Sciences: Supplier of single-use Corning CellSTACK and Ascent bioreactor systems for cell culture and bioprocess applications. Comparable single-use offering targeted at cell therapy and biopharma with established commercial channels.
• Cytiva: Large-scale bioprocessing incumbent offering Xuri cell expansion systems, single-use bioreactors, and process development tools across cell therapy and biopharma. Overlaps with BioThrust in bioreactor-based cell expansion but as part of a much broader portfolio.
• Eppendorf: Manufacturer of BioFlo and DASbox bioreactor systems spanning benchtop to pilot/production scales. Comparable stirred-tank and single-use bioreactor offerings with established presence in bioprocess development labs.

Direct peers

• PBS Biotech: Single-use bioreactor vendor specializing in cell therapy and viral vector manufacturing with vertical-wheel mixing. Directly comparable to BioThrust's ComfyCell as a single-use platform aimed at sensitive-cell cultivation and cell therapy scale-up.
• Cellexus Cellbag Systems: Developer of single-use, airlift-driven bioreactor systems (Cellmaker) for cell culture and microbial fermentation. Comparable as a single-use, gentle-mixing alternative to stirred-tank bioreactors targeting cell therapy and biologics.
• ABEC: Custom single-use bioreactor systems and process solutions for cell therapy, vaccines, and biopharma at clinical and commercial scale. Comparable engineered bioreactor platform with similar customer base in cell therapy CDMOs.

Emerging players

• Miltenyi Biotec: Provider of cell therapy manufacturing solutions including the Prodigy platform for automated cell processing. Comparable focus on cell therapy manufacturing tooling but emphasizes closed-system cell processing over stirred bioreactor culture.
• Distek Inc. Specialist in benchtop and pilot-scale bioreactor systems (BIOne, model 510) plus instrumentation and PAT software for bioprocess development. Comparable as a focused bioreactor instrumentation vendor serving similar development-stage customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biothrust-de

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioThrust